<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786409</url>
  </required_header>
  <id_info>
    <org_study_id>15960A</org_study_id>
    <secondary_id>MERCK: MISP for Gardasil#33598</secondary_id>
    <nct_id>NCT00786409</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women</brief_title>
  <official_title>Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of the HPV vaccine
      Gardasil in young women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female patients with systemic lupus erythematosus (SLE) have been found have higher rates of
      persistent HPV infections and precancerous lesions compared to the healthy population. The
      HPV vaccine Gardasil has been found to be safe and efficacious in females aged 9 to 26 years.
      There are no data on the immunogenicity and safety of Gardasil in females with SLE. Immune
      dysfunction related to SLE itself and the immunosuppression secondary to treatment of SLE
      might prevent patients with SLE from developing an adequate immune response to the vaccine.
      Also, theoretically, the vaccine might induce a disease exacerbation or production of new
      autoantibodies.

      The purpose of this study is to evaluate immunogenicity and safety of Gardasil and its
      effects on autoantibody profile in female SLE patients aged 9-26 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV 6 Seroconversion</measure>
    <time_frame>7 months</time_frame>
    <description>Percent Seropositive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 6 GMT</measure>
    <time_frame>7 months</time_frame>
    <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 11 Seroconversion</measure>
    <time_frame>7 months</time_frame>
    <description>% Seropositive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 11 GMT</measure>
    <time_frame>7 months</time_frame>
    <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 16 Seroconversion</measure>
    <time_frame>7 months</time_frame>
    <description>% Seropositive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 16 GMT</measure>
    <time_frame>7 months</time_frame>
    <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 18 Seroconversion</measure>
    <time_frame>7 months</time_frame>
    <description>% Seropositive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV 18 GMT</measure>
    <time_frame>7 months</time_frame>
    <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SLEDAI Change Score</measure>
    <time_frame>7 months</time_frame>
    <description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): change from baseline to 7 months. The SLEDAI scale is a weighted sum of 16 clinical and 8 laboratory items. Scores range from 0 to 105 with higher scores indicating worse outcome. The variable analyzed here is the 7 month score minus the baseline score. Therefore negative values indicate an improvement in outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction or Increase of Autoantibodies (Conversion From Negative Anti-RNP to Positive Anti-RNP) Anti-RNP</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction or Increase of Autoantibodies (Conversion From Negative Smith to Positive Smith)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction or Increase of Autoantibodies (Conversion From Lupus Anticoagulant Negative to Lupus Anticoagulant Positive)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Gardasil</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.</description>
    <arm_group_label>Gardasil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 9 to 26 years of age

          -  Gender: Female

          -  All patients must fulfill the revised American College of Rheumatology Classification
             Criteria for SLE diagnosis.

          -  Current SLEDAI score â‰¤ 6

          -  Written, witnessed informed consent and/or assent will be obtained from the subject
             and the subject's parents (if under 18 years of age) or legally acceptable
             representative prior to enrollment

        Exclusion Criteria:

          -  Acute exacerbation of disease within past 30 days which required increase in
             corticosteroid dose, initiation of a new immunosuppressive medication, or
             hospitalization

          -  Current SLEDAI score &gt; 6

          -  Patients who have received rituximab in the last 6 months, or are currently on
             cyclophosphamide treatment

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccine

          -  Previous administration of any HPV vaccine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Wagner-Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, Cason J. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007 May 15;57(4):619-25.</citation>
    <PMID>17471531</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <results_first_submitted>November 8, 2016</results_first_submitted>
  <results_first_submitted_qc>February 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2018</results_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gardasil Vaccine</title>
          <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gardasil Vaccine</title>
          <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" lower_limit="12" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 6 Seroconversion</title>
        <description>Percent Seropositive</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 6 Seroconversion</title>
          <description>Percent Seropositive</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 6 GMT</title>
        <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 6 GMT</title>
          <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>mMu/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427.0" lower_limit="203.4" upper_limit="903.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 11 Seroconversion</title>
        <description>% Seropositive</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 11 Seroconversion</title>
          <description>% Seropositive</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 11 GMT</title>
        <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 11 GMT</title>
          <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>mMu/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.7" lower_limit="303.6" upper_limit="1173.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 16 Seroconversion</title>
        <description>% Seropositive</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 16 Seroconversion</title>
          <description>% Seropositive</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 16 GMT</title>
        <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 16 GMT</title>
          <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>mMu/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2263.2" lower_limit="1019.3" upper_limit="5024.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 18 Seroconversion</title>
        <description>% Seropositive</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 18 Seroconversion</title>
          <description>% Seropositive</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV 18 GMT</title>
        <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
        <time_frame>7 months</time_frame>
        <population>4 patients did not have month 7 samples available for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HPV 18 GMT</title>
          <description>Geometric mean titre in milli-Merck units per ml (mMu/ml)</description>
          <population>4 patients did not have month 7 samples available for analysis</population>
          <units>mMu/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.9" lower_limit="159.8" upper_limit="689.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SLEDAI Change Score</title>
        <description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): change from baseline to 7 months. The SLEDAI scale is a weighted sum of 16 clinical and 8 laboratory items. Scores range from 0 to 105 with higher scores indicating worse outcome. The variable analyzed here is the 7 month score minus the baseline score. Therefore negative values indicate an improvement in outcome.</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>SLEDAI Change Score</title>
          <description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): change from baseline to 7 months. The SLEDAI scale is a weighted sum of 16 clinical and 8 laboratory items. Scores range from 0 to 105 with higher scores indicating worse outcome. The variable analyzed here is the 7 month score minus the baseline score. Therefore negative values indicate an improvement in outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" lower_limit="-2.85" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction or Increase of Autoantibodies (Conversion From Negative Anti-RNP to Positive Anti-RNP) Anti-RNP</title>
        <time_frame>7 months</time_frame>
        <population>8 patients were negative for anti-RNP at entry</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Induction or Increase of Autoantibodies (Conversion From Negative Anti-RNP to Positive Anti-RNP) Anti-RNP</title>
          <population>8 patients were negative for anti-RNP at entry</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction or Increase of Autoantibodies (Conversion From Negative Smith to Positive Smith)</title>
        <time_frame>7 months</time_frame>
        <population>13 patients were Smith negative at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Induction or Increase of Autoantibodies (Conversion From Negative Smith to Positive Smith)</title>
          <population>13 patients were Smith negative at entry.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction or Increase of Autoantibodies (Conversion From Lupus Anticoagulant Negative to Lupus Anticoagulant Positive)</title>
        <time_frame>7 months</time_frame>
        <population>17 patients were Lupus anticoagulant negative at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine</title>
            <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Induction or Increase of Autoantibodies (Conversion From Lupus Anticoagulant Negative to Lupus Anticoagulant Positive)</title>
          <population>17 patients were Lupus anticoagulant negative at entry.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gardasil Vaccine</title>
          <description>0.5 ml Gardasil vaccine at months 0, 2, and 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Progression of Class IV Nephritis to Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Wagner-Weinter, MD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-2245</phone>
      <email>lww@uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

